Advertisement
ALNY or INCY or VRTX
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Incyte Corporation (INCY) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- ALNY leads with strong revenue growth over 80% YoY in 2025, driven by TTR amyloidosis drugs, but trades at a high P/E ratio above 130x amid YTD declines of around 20%.
- INCY offers attractive valuation with P/E around 14-15x, solid profitability, and YTD performance outperforming peers despite recent dips, supported by diversified oncology portfolio.
- VRTX provides market-leading stability with $12B+ annual revenue from CF franchise and expanding pipeline in pain/kidney, but YTD flat to negative amid high P/E over 20x.
- All three biotech leaders show relative 1-year gains, with INCY at ~50%, but recent momentum favors growth catalysts like ALNY's partnerships over valuation discounts at INCY.
- Sector risks include pipeline execution and pricing pressures, balanced by strong cash positions across the trio.
Introduction
Alnylam Pharmaceuticals (ALNY), Incyte Corporation (INCY), and Vertex Pharmaceuticals (VRTX) represent leading biotech firms focused on innovative therapies in rare diseases, oncology, and genetic disorders. This stock comparison evaluates their recent performance, growth drivers, and market positioning amid evolving biotech sentiment. Traders seeking momentum plays and investors eyeing long-term catalysts in RNAi, JAK inhibitors, and CF modulators will find value in contrasting their trajectories, valuations, and pipeline progress for informed relative performance decisions.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY), a pioneer in RNA interference (RNAi) therapeutics—a technology silencing disease-causing genes—focuses on rare genetic diseases. Its portfolio includes AMVUTTRA and ONPATTRO for hereditary ATTR amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. In recent market activity, ALNY reported full-year 2025 net product revenues of nearly $3 billion, up 81% YoY, with Q4 at $995 million surging 121%, achieving GAAP profitability. Shares experienced volatility post-earnings due to slight revenue misses and guidance nuances but rebounded on optimism for 2026 revenue projections of $4.9-$5.3 billion. Recent weeks saw partnerships like the Tenaya Therapeutics collaboration for cardiovascular RNAi therapies and positive data on vutrisiran, bolstering sentiment despite YTD declines around 20% from peaks near $500. Trading around $316 with a ~$42B market cap, performance reflects high growth offset by elevated valuations (P/E ~135x).
INCY Overview and Recent Performance
Incyte Corporation (INCY) specializes in small-molecule therapeutics for hematology/oncology and inflammation/autoimmunity, with flagship JAKAFI (ruxolitinib) for myeloproliferative neoplasms alongside PEMAZYRE, ICLUSIG, and newer launches like NIKTIMVO and ZYNYZ. Recent quarters highlighted robust revenue growth, with Q4 2025 totals up 27.8% YoY to $1.51B despite EPS misses prompting share dips. In recent weeks, positive 54-week data for povorcitinib in hidradenitis suppurativa at AAD 2026 and EC approval for ZYNYZ in anal cancer enhanced pipeline visibility, alongside executive appointments signaling strategic focus. Shares, around $90 with ~$18B market cap, posted strong 1-year gains near 50% but YTD softness (~-8%), trading at compelling P/E ~14x amid stable EBITDA and lower debt versus peers. Sentiment balances commercial execution with diversification beyond JAKAFI.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals (VRTX) dominates cystic fibrosis (CF) with TRIKAFTA and next-gen ALYFTREK, expanding into sickle cell (CASGEVY), pain (JOURNAVX), and kidney diseases. Full-year 2025 revenues hit $12B, up 9%, with Q4 at $3.19B rising 10%; 2026 guidance targets $12.95-$13.1B including non-CF growth. Recent developments include positive Phase 3 interim for povetacicept in IgA nephropathy (52% proteinuria reduction) and JOURNAVX data showing >90% opioid-free pain management post-surgery. Shares near $443 with $112B+ market cap reflect stability but recent pressure, with YTD ~2% and 1-year mixed, at P/E ~23x. Performance draws strength from CF durability and diversification catalysts, tempered by launch ramps for newer assets.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases over 25 top-performing AI trading bots curated from a total of 351 bots that trade thousands of different tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like technical analysis, price action, and fundamental signals, operating on timeframes from 5-minute (Expert) to 60-minute (Intermediate), with risk levels from low to high volatility. Available as AI Trading Signal Agents for real-time alerts (no balance minimum), Virtual Agents with customizable balances and risk management, or Brokerage Agents via Tickeron brokerage, only the most suitable for prevailing market conditions earn a trending spot based on AI analysis. Explore these bots to leverage advanced pattern recognition and backtested edges tailored to current trends.
Head-to-Head Comparison
ALNY, INCY, and VRTX diverge in business models: ALNY's RNAi platform targets rare genetic silencing, INCY emphasizes small-molecule oncology/inflammation diversity, and VRTX leverages CF modulator dominance with cell/gene therapies. Growth drivers highlight ALNY's explosive TTR sales (71% projected 2026 rise) versus INCY's steady JAKAFI expansions and VRTX's non-CF ramps (e.g., CASGEVY, povetacicept). Recent momentum shows ALNY rebounding from earnings dips on partnerships, INCY resilient post-pipeline wins despite YTD lags, and VRTX steady amid Phase 3 successes but softer 1-year returns.
Risk factors include ALNY's TTR concentration and high valuation sensitivity (P/E 135x), INCY's patent cliffs on JAKAFI balanced by lower debt/cash strength, and VRTX's launch execution in competitive pain/kidney spaces. Sector exposure skews rare/genetic for ALNY/VRTX, broader oncology for INCY. Valuation contrasts sharply: INCY's ~14x P/E offers value versus ALNY's premium growth multiple and VRTX's mature 23x. Market sentiment favors ALNY's upside catalysts, INCY's profitability, and VRTX's cash flow stability (~$12B cash).
Tickeron AI Verdict
Tickeron’s AI currently favors INCY for its trend consistency, low-teens P/E valuation, positive relative YTD stability, and diversified revenue reducing biotech volatility. While ALNY tempts with superior growth and catalysts like ATTR dominance, its stretched multiples introduce uncertainty; VRTX excels in profitability but lags momentum. Probabilistic edge leans to INCY's risk-reward balance in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileINCY’s FA Score has 1 green FA rating(s), and VRTX’s FA Score reflects 0 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- INCY’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 2 TA indicator(s) are bullish while INCY’s TA Score has 5 bullish TA indicator(s), and VRTX’s TA Score reflects 4 bullish TA indicator(s).
- ALNY’s TA Score: 2 bullish, 7 bearish.
- INCY’s TA Score: 5 bullish, 4 bearish.
- VRTX’s TA Score: 4 bullish, 3 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -3.87% price change this week, while INCY (@Biotechnology) price change was +1.82% , and VRTX (@Biotechnology) price fluctuated +1.13% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
INCY is expected to report earnings on Apr 28, 2026.
VRTX is expected to report earnings on May 04, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ALNY | INCY | VRTX | |
| Capitalization | 41.3B | 19.5B | 112B |
| EBITDA | 631M | 1.76B | 4.87B |
| Gain YTD | -22.127 | -0.962 | -2.682 |
| P/E Ratio | 132.90 | 15.26 | 28.80 |
| Revenue | 3.71B | 5.14B | 12B |
| Total Cash | 2.91B | 3.58B | 6.61B |
| Total Debt | 1.28B | 40.4M | 2.03B |
ALNY | INCY | VRTX | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 69 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 69 Overvalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 53 | 72 | 35 | |
SMR RATING 1..100 | 15 | 32 | 40 | |
PRICE GROWTH RATING 1..100 | 60 | 49 | 60 | |
P/E GROWTH RATING 1..100 | 100 | 100 | 53 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCY's Valuation (69) in the Biotechnology industry is in the same range as VRTX (80) and is in the same range as ALNY (94). This means that INCY's stock grew similarly to VRTX’s and similarly to ALNY’s over the last 12 months.
VRTX's Profit vs Risk Rating (35) in the Biotechnology industry is in the same range as ALNY (53) and is somewhat better than the same rating for INCY (72). This means that VRTX's stock grew similarly to ALNY’s and somewhat faster than INCY’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is in the same range as INCY (32) and is in the same range as VRTX (40). This means that ALNY's stock grew similarly to INCY’s and similarly to VRTX’s over the last 12 months.
INCY's Price Growth Rating (49) in the Biotechnology industry is in the same range as ALNY (60) and is in the same range as VRTX (60). This means that INCY's stock grew similarly to ALNY’s and similarly to VRTX’s over the last 12 months.
VRTX's P/E Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for INCY (100) and is somewhat better than the same rating for ALNY (100). This means that VRTX's stock grew somewhat faster than INCY’s and somewhat faster than ALNY’s over the last 12 months.
| ALNY | INCY | VRTX | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 63% | N/A |
| Stochastic ODDS (%) | 2 days ago 63% | 2 days ago 57% | 2 days ago 64% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 63% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 67% | 2 days ago 62% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 63% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 69% | 2 days ago 60% | 2 days ago 36% |
| Advances ODDS (%) | 5 days ago 76% | 10 days ago 61% | 5 days ago 63% |
| Declines ODDS (%) | 2 days ago 66% | 3 days ago 60% | 3 days ago 43% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 67% | N/A |
| Aroon ODDS (%) | 2 days ago 71% | 2 days ago 60% | 2 days ago 30% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CRPT | 14.93 | 0.85 | +6.07% |
| First Trust SkyBdg Cry Idt & Dgt Eco ETF | |||
| NVDX | 18.42 | 0.59 | +3.34% |
| T-REX 2X Long NVIDIA Daily Target ETF | |||
| CGBL | 36.82 | 0.45 | +1.24% |
| Capital Group Core Balanced ETF | |||
| XLVI | 25.18 | 0.25 | +1.00% |
| State Street®HlthCrSelSectSPDR®PrmETF | |||
| RXD | 9.83 | -0.30 | -2.93% |
| ProShares UltraShort Health Care | |||
VRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with CRSP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To VRTX | 1D Price Change % | ||
|---|---|---|---|---|
| VRTX | 100% | +1.27% | ||
| CRSP - VRTX | 37% Loosely correlated | +4.07% | ||
| EDIT - VRTX | 37% Loosely correlated | +4.03% | ||
| INCY - VRTX | 34% Loosely correlated | +2.62% | ||
| MRNA - VRTX | 34% Loosely correlated | -1.76% | ||
| MGTX - VRTX | 34% Loosely correlated | +6.65% | ||
More | ||||